Cumberland Pharmaceuticals Receives FDA Notification Setting Sept 2019 As PDUFA Action Date For Approval Decision Regarding NDA For Methotrexate Product Line; Remitted Payment Of $1.3M To FDA For PDUFA Application Fee Associated With Methotrexate